X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Growth in innovative, value-based contracts holds promise for the health system and for patients

By Katie Koziara  |    September 24, 2020
The extraordinary financial pressure COVID-19 is creating for the U.S. economy underscores the need for a renewed push toward a more value-driven health care system that prioritizes patient access...   Read More

Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A

By Stephen J. Ubl  |    September 23, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent...   Read More

Study finds middlemen excluded nearly 850 medicines from formularies this year

By Katie Koziara  |    September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies...   Read More

Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.

By Stephen J. Ubl  |    September 17, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing potential therapeutics to treat COVID-19 and vaccines to prevent...   Read More

Recent administration actions undermine patient assistance programs

By Nicole Longo  |    September 16, 2020
While all eyes and ears are focused on COVID-19 and beating this pandemic, the administration has pursued harmful policy changes that we can’t let slip under the radar. In two back-to-back...   Read More

Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19

By Guest Contributor  |    September 16, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem

By Jocelyn Ulrich  |    September 16, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

National Medicare Education Week: The history of Medicare Part D

By Tom Wilbur  |    September 15, 2020
Today, in honor of National Medicare Education Week, we’ll be taking a quick look back at the history of Medicare, specifically the Medicare Part D prescription drug benefit .   Read More

PhRMA member companies invested $83 billion in research and development last year

By Tim McClung  |    September 10, 2020
PhRMA member companies invested $83 billion in research and development (R&D) in 2019, the highest level of investment on record, according to the 2020 PhRMA member annual survey. Over the past...   Read More

PhRMA will continue to advocate for equity within our industry

By Yolanda Hutchins  |    September 10, 2020
When I first started at PhRMA two and a half years ago, our organization was just starting to talk about how we could increase and activate our commitment to diversity & inclusion (D&I). As senior...   Read More

Coming together to fight COVID-19: A conversation with Joaquin Duato, vice chairman of the executive committee at Johnson & Johnson

By Stephen J. Ubl  |    September 9, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent...   Read More

Innovative contracts drive access for patients and value for the system

By Katie Koziara  |    September 9, 2020
Our health care system is far from perfect, but there are solutions that will help address patient affordability concerns without sacrificing innovation, access or quality of care. For example,...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    September 8, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi

By Stephen J. Ubl  |    September 2, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent...   Read More

How Medicare Part D supports patients

By Tom Wilbur  |    September 1, 2020
Since 2006, Medicare Part D has offered seniors and people living with disabilities affordable access to life-saving treatments through comprehensive prescription drug coverage. The benefit has...   Read More

Three ways the pharmaceutical industry can positively impact health equity

By Guest Contributor  |    September 1, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates